HIVE Blockchain Technologies (CVE:HIV – Get Free Report) was upgraded by stock analysts at Keefe, Bruyette & Woods to a “moderate buy” rating in a note issued to investors on Wednesday,Zacks.com reports.
HIV has been the subject of a number of other research reports. Roth Capital upgraded shares of HIVE Blockchain Technologies to a “strong-buy” rating in a research note on Wednesday, December 18th. Cantor Fitzgerald upgraded shares of HIVE Blockchain Technologies to a “strong-buy” rating in a research report on Tuesday, October 29th. Finally, Northland Capmk raised HIVE Blockchain Technologies to a “strong-buy” rating in a research report on Thursday, September 19th. Four equities research analysts have rated the stock with a strong buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Strong Buy”.
View Our Latest Research Report on HIV
HIVE Blockchain Technologies Stock Performance
Read More
- Five stocks we like better than HIVE Blockchain Technologies
- The 3 Best Blue-Chip Stocks to Buy Now
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Do ETFs Pay Dividends? What You Need to Know
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Following Congress Stock Trades
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for HIVE Blockchain Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HIVE Blockchain Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
